Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: a potential modality for inducing long-term survival in selected patients
/in Hyperthermia /von 2012-03-23 / Lung Cancer 2012 Jul;77(1):140-5Extracellular vesicles–vehicles that spread cancer genes
/in Exosome, International Publications /von 2012-03-22 / Bioessays 2012 Jun;34(6):489-97Cancer immunotherapy via dendritic cells
/in Dendritic Cells, International Publications /von 2012-03-22 / Nat. Rev. Cancer 2012 Mar;12(4):265-77The blockade of immune checkpoints in cancer immunotherapy
/in Checkpoint-Inhibitors, International Publications /von 2012-03-22 / Nat. Rev. Cancer 2012 Mar;12(4):252-64Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-804Immunotherapy using dendritic cells against multiple myeloma: how to improve?
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2012-03-15 / Clin. Dev. Immunol. 2012;2012:397648Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination
/in Dendritic Cells, International Publications /von 2012-03-15 / J. Biomed. Biotechnol. 2012;2012:425476Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2012-03-08 / Arch. Virol. 2012 Jun;157(6):1011-8Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
/in Breast Cancer, Dendritic Cells, International Publications /von 2012-03-07 / Breast Cancer Res. 2012 Mar;14(2):R39
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution